Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

First Albany Cuts OrthoLogic to Neutral


First Albany downgraded OrthoLogic (OLGC) to neutral from buy, explaining that the drug developer's trial of the wrist fracture treatment Chrysalin has failed.

Analyst William Plovanic notes that company management expects to reevaluate its strategy going forward, including a full examination of another fracture study. The analyst believes commercialization of any product has been pushed off significantly. With no revenue in sight, he believes the stock will likely trade around its cash position of $2.20 per share.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus